CN106943420A - 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 - Google Patents

三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 Download PDF

Info

Publication number
CN106943420A
CN106943420A CN201611266703.4A CN201611266703A CN106943420A CN 106943420 A CN106943420 A CN 106943420A CN 201611266703 A CN201611266703 A CN 201611266703A CN 106943420 A CN106943420 A CN 106943420A
Authority
CN
China
Prior art keywords
fatty liver
liver
alcoholic fatty
triacetyl
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611266703.4A
Other languages
English (en)
Chinese (zh)
Inventor
朱海波
史会杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Gushen Life Health Technology Co ltd
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Institute of Materia Medica of CAMS and PUMC
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Materia Medica of CAMS and PUMC, Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Institute of Materia Medica of CAMS and PUMC
Priority to CN202410227642.9A priority Critical patent/CN118178446A/zh
Publication of CN106943420A publication Critical patent/CN106943420A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201611266703.4A 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 Pending CN106943420A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410227642.9A CN118178446A (zh) 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201511034199 2015-12-31
CN2015110341990 2015-12-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410227642.9A Division CN118178446A (zh) 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Publications (1)

Publication Number Publication Date
CN106943420A true CN106943420A (zh) 2017-07-14

Family

ID=59224622

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611266703.4A Pending CN106943420A (zh) 2015-12-31 2016-12-31 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
CN202410227642.9A Pending CN118178446A (zh) 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410227642.9A Pending CN118178446A (zh) 2015-12-31 2016-12-31 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用

Country Status (11)

Country Link
US (1) US11058703B2 (enExample)
EP (1) EP3398604A4 (enExample)
JP (1) JP7382716B2 (enExample)
KR (1) KR102676056B1 (enExample)
CN (2) CN106943420A (enExample)
AU (1) AU2016383376B2 (enExample)
CA (1) CA3010097C (enExample)
HK (1) HK1255689A1 (enExample)
RU (1) RU2759916C2 (enExample)
WO (1) WO2017114413A1 (enExample)
ZA (1) ZA201805080B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
WO2025103336A1 (zh) * 2023-11-15 2025-05-22 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
KR20210016407A (ko) * 2018-06-05 2021-02-15 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 대사 장애 및 비알코올성 지방 간 질환의 치료를 위한 활성제 및 그 사용 방법
CN114869901B (zh) * 2022-05-06 2023-10-27 安徽医科大学 马鞭草苷在治疗酒精性肝损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1563152A (zh) * 2004-03-19 2005-01-12 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
CN101874036A (zh) * 2008-10-06 2010-10-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
CN104211747A (zh) * 2013-05-29 2014-12-17 中国医学科学院药物研究所 5’-磷酸-n6-(3-羟基苯基）腺苷的制备及医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005132812A (ja) 2003-10-08 2005-05-26 Kobayashi Pharmaceut Co Ltd シイタケ菌糸体抽出物の分画物およびその用途
JP2007210926A (ja) 2006-02-08 2007-08-23 Tokyo Univ Of Pharmacy & Life Science ピラジンカルボン酸化合物からなる薬剤、及び食餌
JP5688229B2 (ja) 2010-03-19 2015-03-25 国立大学法人名古屋大学 肝保護作用を有するタンパク質、肝障害予防・保護用化合物のスクリーニング方法
CN102125580A (zh) * 2011-01-17 2011-07-20 泰山医学院 三乙酰基-3-羟基苯基腺苷thpa在制药中的应用
ME02312B (me) * 2011-04-22 2016-06-20 Pfizer DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
AU2013204500A1 (en) 2012-09-21 2014-04-10 Barbara Jane Badenoch-Jones Novel AMPK agonist compositions and methods of use
CN103191145A (zh) 2013-03-27 2013-07-10 南京理工大学 腺苷及其衍生物在防治药物性肝损伤中的应用
US9827222B2 (en) 2013-07-01 2017-11-28 Emory University Treating or preventing nephrogenic diabetes insipidus
CN104546887B (zh) * 2013-10-09 2018-10-30 中国医学科学院药物研究所 虫草素衍生物治疗炎症疾病的用途
CN105663152A (zh) 2014-11-19 2016-06-15 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用
CN107334775A (zh) * 2016-03-14 2017-11-10 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1563152A (zh) * 2004-03-19 2005-01-12 四川大学 聚合物型含磷阻燃剂及其制备方法和用途
CN101874036A (zh) * 2008-10-06 2010-10-27 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
CN104211747A (zh) * 2013-05-29 2014-12-17 中国医学科学院药物研究所 5’-磷酸-n6-(3-羟基苯基）腺苷的制备及医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PENG GUO ET AL.: "The adenosine derivative 2",3",5"-tri-O-acetyl-N6-(3-hydroxylaniline)adenosine activates AMPK and regulates lipid metabolism in vitro and in vivo", 《LIFE SCIENCES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821313A (zh) * 2019-04-17 2020-10-27 江苏天士力帝益药业有限公司 三乙酰基-3-羟基苯基腺苷在制备抑制心脏纤维化的药物中的应用
WO2025103336A1 (zh) * 2023-11-15 2025-05-22 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在制备运动模拟药物中的应用

Also Published As

Publication number Publication date
JP7382716B2 (ja) 2023-11-17
US20190022120A1 (en) 2019-01-24
AU2016383376B2 (en) 2022-07-28
CA3010097C (en) 2023-08-22
KR20180100152A (ko) 2018-09-07
RU2018126158A (ru) 2020-01-31
AU2016383376A1 (en) 2018-07-12
EP3398604A1 (en) 2018-11-07
US11058703B2 (en) 2021-07-13
JP2019500379A (ja) 2019-01-10
KR102676056B1 (ko) 2024-06-19
RU2018126158A3 (enExample) 2020-03-11
CA3010097A1 (en) 2017-07-06
ZA201805080B (en) 2019-10-30
EP3398604A4 (en) 2019-06-19
WO2017114413A1 (zh) 2017-07-06
CN118178446A (zh) 2024-06-14
RU2759916C2 (ru) 2021-11-18
HK1255689A1 (en) 2019-08-23

Similar Documents

Publication Publication Date Title
CN106943420A (zh) 三乙酰基‑3‑羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用
CN116785301A (zh) 含醋酸阿比特龙的药物组合物及其制备方法和应用
CN117018091A (zh) 奇楠提取物对ampk的激活作用
Wang et al. Endoplasmic reticulum stress regulates autophagic response that is involved in Saikosaponin a-induced liver cell damage
CN106176773A (zh) 盐酸小檗碱和水苏糖组成的组合物及其应用
US20250114423A1 (en) Use of mulberry twig alkaloids in preparation of drug for treating polycystic ovarian syndrome
CN101966182B (zh) 复方脑保护制剂及其制备方法
CN115969914A (zh) 槐榆组合物在制备预防或治疗炎症性肠病药物中的应用
KR20150130352A (ko) 지방간 질환을 치료하는 방법
CN110368414A (zh) 一种预防和/或治疗非酒精性脂肪肝病的药物制剂
CN107334775A (zh) 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用
WO2005002568A1 (fr) Utilisation de 1-n-butylphtalide pour la prevention ou les traitements de la demence
CN109303921B (zh) Fxr激动剂与sirt1激动剂联用在制备抗肝纤维化药物中的应用
CN102641342B (zh) 一种治疗肾病的中药提取物和制备方法
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
CN103239436A (zh) 异鼠李素在制备用于阿霉素辅助治疗药物中的应用
CN111686239B (zh) 抗真菌化合物的应用
CN102247349B (zh) 丹酚酸a预防和/或治疗糖尿病所致肝脏病变的用途
CN113368182A (zh) 一种预防或治疗糖尿病脑病的中药组合物及其用途
RU2836760C1 (ru) Способ получения липосомальной лекарственной формы ацетилцистеина
CN117860774B (zh) 甲钴胺与水林佳组合药物在治疗非酒精性脂肪肝炎中的应用
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
CN103550211A (zh) 盐酸小檗碱在制备预防和/或治疗急慢性酒精性肝病药物中的应用
CN110833550B (zh) 吡唑并嘧啶衍生物在治疗急性胰腺炎致肝损伤的用途
CN117398433A (zh) 一种丹参保心茶在制备防治认知功能障碍药物中的新应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211027

Address after: 100050 Beijing city Xuanwu District Xiannongtan Street No. 1

Applicant after: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Applicant after: BEIJING GUSHEN LIFE HEALTH TECHNOLOGY Co.,Ltd.

Address before: 100050 Beijing city Xuanwu District Xiannongtan Street No. 1

Applicant before: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES

Applicant before: JIANGSU TASLY DIYI PHARMACEUTICAL Co.,Ltd.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20170714

RJ01 Rejection of invention patent application after publication